These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 28660496)

  • 1. Role of Cost on Failure to Access Prescribed Pharmaceuticals: The Case of Statins.
    McRae I; van Gool K; Hall J; Yen L
    Appl Health Econ Health Policy; 2017 Oct; 15(5):625-634. PubMed ID: 28660496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Patient Reimbursement Timing and Patient Out-of-Pocket Expenses on Medication Adherence in Patients Covered by Private Drug Insurance Plans.
    Després F; Forget A; Kettani FZ; Blais L
    J Manag Care Spec Pharm; 2016 May; 22(5):539-47. PubMed ID: 27123915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia.
    Hynd A; Roughead EE; Preen DB; Glover J; Bulsara M; Semmens J
    Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1091-9. PubMed ID: 18942671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure to access prescribed pharmaceuticals by older patients with chronic conditions.
    McRae I; van Gool K; Hall J; Yen L; Wright M
    Aust Health Rev; 2020 Apr; 44(2):270-276. PubMed ID: 30827330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of reduced copayments on discontinuation and adherence failure to statin medication in Australia.
    Knott RJ; Petrie DJ; Heeley EL; Chalmers JP; Clarke PM
    Health Policy; 2015 May; 119(5):620-7. PubMed ID: 25724823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of consumer copayments for subsidised medicines on health services use and outcomes: a protocol using linked administrative data from Western Australia.
    Seaman KL; Sanfilippo FM; Roughead EE; Bulsara MK; Kemp-Casey A; Bulsara C; Watts GF; Preen D
    BMJ Open; 2017 Jun; 7(6):e013691. PubMed ID: 28637723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-related non-adherence to prescribed medicines among older adults: a cross-sectional analysis of a survey in 11 developed countries.
    Morgan SG; Lee A
    BMJ Open; 2017 Jan; 7(1):e014287. PubMed ID: 28143838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost driver analysis of statin expenditure on Australia's Pharmaceutical Benefits Scheme.
    Thai LP; Moss JR; Godman B; Vitry AI
    Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):419-33. PubMed ID: 26707482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased patient co-payments and changes in PBS-subsidised prescription medicines dispensed in Western Australia.
    Hynd A; Roughead EE; Preen DB; Glover J; Bulsara M; Semmens J
    Aust N Z J Public Health; 2009 Jun; 33(3):246-52. PubMed ID: 19630844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of prescription drug costs in the United States and the United Kingdom, Part 1: statins.
    Jick H; Wilson A; Wiggins P; Chamberlin DP
    Pharmacotherapy; 2012 Jan; 32(1):1-6. PubMed ID: 22392823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolutions in both co-payment and generic market share for common medication in the Belgian reference pricing system.
    Fraeyman J; Verbelen M; Hens N; Van Hal G; De Loof H; Beutels P
    Appl Health Econ Health Policy; 2013 Oct; 11(5):543-52. PubMed ID: 24062144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reasons why insured consumers co-pay for medicines at retail pharmacies in Pretoria, South Africa.
    Mpanza NM; Bradley H; Laing R
    Afr J Prim Health Care Fam Med; 2019 Mar; 11(1):e1-e6. PubMed ID: 31038333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors influencing adherence in long-term use of statins.
    Warren JR; Falster MO; Fox D; Jorm L
    Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1298-307. PubMed ID: 24105731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of copayment with likelihood and level of adherence in new users of statins: a retrospective cohort study.
    Watanabe JH; Kazerooni R; Bounthavong M
    J Manag Care Pharm; 2014 Jan; 20(1):43-50. PubMed ID: 24372459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of health insurance coverage in women's access to prescription medicines.
    Ranji UR; Wyn R; Salganicoff A; Yu H
    Womens Health Issues; 2007; 17(6):360-6. PubMed ID: 18042485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantifying the use of the statin antilipemic drugs: comparisons and contrasts between Nova Scotia, Canada, and Queensland, Australia.
    Cooke C; Nissen L; Sketris I; Tett SE
    Clin Ther; 2005 Apr; 27(4):497-508. PubMed ID: 15922822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies used by adults to reduce their prescription drug costs.
    Cohen RA; Kirzinger WK; Gindi RM
    NCHS Data Brief; 2013 Apr; (119):1-8. PubMed ID: 23742848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Affordable and equitable access to subsidised outpatient medicines? Analysis of co-payments under the Additional Drug Package in Kyrgyzstan.
    Vogler S; Schneider P; Dedet G; Bak Pedersen H
    Int J Equity Health; 2019 Jun; 18(1):89. PubMed ID: 31196109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pricing and reimbursement of pharmaceuticals in Italy.
    Folino-Gallo P; Montilla S; Bruzzone M; Martini N
    Eur J Health Econ; 2008 Aug; 9(3):305-10. PubMed ID: 18566845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of regional co-payment and national reimbursement criteria on statins use in Italy: an interrupted time-series analysis.
    Damiani G; Federico B; Anselmi A; Bianchi CB; Silvestrini G; Iodice L; Navarra P; Da Cas R; Raschetti R; Ricciardi W
    BMC Health Serv Res; 2014 Jan; 14():6. PubMed ID: 24393340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.